Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma (ALPI)

Singapore National Eye Centre

Status and phase

Unknown

Phase 3

Conditions

Glaucoma

Treatments

Procedure: Argon Laser Iridoplasty

Drug: Travatan/ Timolol/Azopt

Study type

Interventional

Funder types

Other

Identifiers

NCT00980473

R399/57/2004

Details and patient eligibility

About

Glaucoma is the leading cause of irreversible blindness worldwide. With ageing of the population, glaucoma morbidity will rise, causing increased health care costs and economic burden for a condition in which visual loss, once established, cannot be reversed. In contrast to western countries, primary angle closure glaucoma (PACG) is a major form of glaucoma in Asia. In a recent population based survey in Singapore, the prevalence of glaucoma was 3.2% in the Chinese population over 40. Glaucoma was the leading cause of blindness, with PACG the most visually destructive form of the disease.

Laser iridotomy is the current first line treatment for PACG. It acts by relieving pupil block, which in turn may reduce intraocular pressure (IOP) and prevent progression of glaucoma. However recent data indicate that iridotomy is not successful in controlling IOP in the long term, and the majority of cases develop a clinically significant rise in IOP requiring medical therapy or surgery.

Argon laser peripheral iridoplasty (ALPI) offers a new therapeutic option for PACG. The procedure consists of placing contraction burns in the iris periphery which results in contraction of the iris stroma and opening of the angle.

The proposed study is a 2-centre randomized controlled trial to determine whether ALPI is an effective and safe treatment in the management of PACG. 210 patients with PACG and high IOP (>21 mmHg) following laser iridotomy will be randomized to receive ALPI or medical treatment to achieve IOP control. Subjects will be followed up for 12 months and the outcome criteria will be the rate of medical treatment and surgery in each group, and the angle width and configuration.

This will be the first RCT worldwide to address the role of ALPI in PACG. The study findings will have great relevance for the prevention of glaucoma blindness in the elderly.

Full description

AIMS AND OBJECTIVES

The primary aim of the study is to determine whether argon laser peripheral iridoplasty (ALPI) is an effective treatment in terms of intraocular pressure (IOP) control for cases of primary angle closure glaucoma (PACG) in which the drainage angle remains narrow following laser iridotomy. Primary outcome measures will be the proportion of patients requiring medical or surgical treatment to maintain IOP control, number of medications required to control IOP at 12 months follow up.

The secondary aim is determine whether ALPI significantly alters the configuration of the drainage angle when compared with conventional treatment (medication) following laser iridotomy. Secondary outcomes will be the change in appearance of the drainage angle based on gonioscopy, ultrasound biomicroscopy and anterior segment OCT at 1, 6 and 12 months follow up.

The safety of ALPI and the detrimental effects of iridoplasty on the corneal endothelium and the lens will also be investigated.

STUDY DESIGN

The study design for this project is a prospective randomized controlled trial. It will not be possible to blind either the subject or observer to the intervention due to the use of laser in the intervention group.

STUDY POPULATION

The study population will be patients with primary angle closure glaucoma attending the Singapore National Eye Centre and National University Hospital, who fulfil the inclusion criteria and are willing to take part in the study.

Wash out regimen

Eligible patients who are already on one or two-glaucoma medications are required to complete a washout period before being randomized. Washout periods will vary according to the previous medication used and are as follows:

Prostaglandin analogues 4 weeks Beta blockers 3 weeks Adrenergic agonist 2 weeks Cholinergic agonist 5 days Carbonic Anhydrase Inhibitors 5 days

Pre-study washout period check

Patients who are on prostaglandin analogues or beta blockers prior to the study will be required to undergo a washout period of 3 and 4 weeks respectively prior to the study. For this group of patients, there will be a safety check during the second week. Patients whose IOP>30 mm Hg during this washout check will be stopped from further washout and be withdrawn from the study.

PLANNED INTERVENTIONS

Iridoplasty group

For those randomised to laser iridoplasty, the procedure will be performed as follows:

A drop of brimonidine will be instilled in to the eye to be treated 15 minutes prior to the procedure. Topical anaesthesia will be administered and an Abrahams lens used for the procedure.

Laser burns will be placed over 360 degrees of the peripheral iris (approximately 25 burns in total).

The argon laser setting used are as follows:

Initial treatment (SEAGIG Guidelines) 28 We request to modify our laser settings for initial treatment in the laser arm to Spot size: 200-500 microns (changed from 500 microns) Power: 150-400 milliwatts (mw) increasing until desired end point is achieved (changed from 100-300mw) Duration: 0.2 -0.5 seconds.

Repeat treatment (one month - three months) Laser settings 29 Spot size: 200 microns Power: 100-300 milliwatts increasing until desired end point is achieved Duration: 0.5 -0.7 seconds.

The patient will be given a 2 week course of topical steroids four times a day for the treated eye.

Intraocular pressure will be checked one hour after the procedure. IOP spikes > 25mmHg will be treated.

RE-TREATMENT

If at follow up the angle remains as narrow as before on gonioscopy and UBM/ ASOCT then one further treatment of ALPI will be given to the patient to try and achieve the endpoint of widening the angle. This treatment will be administered between one and three months

CONTROL GROUP

Those patients randomized to the control group will not undergo further procedures at this visit. The patients will be commenced on topical treatment to lower the IOP. The first line agent for lowering IOP will be a prostaglandin analogue, and a stepwise addition of Timoptol 0.5% or dorzolamide will be implemented until IOP is controlled.

If both eyes of an individual patient fulfil the inclusion criteria they will both undergo intervention as allocated by randomization of the patient. (see randomization and data analysis)

Enrollment

80 estimated patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Persistent narrow angle in the presence of a patent laser peripheral iridotomy. A narrow angle is defined as an angle width of 0-10º in 2 or more quadrants of either eye or where the pigmented trabecular meshwork is not visible in for 2 or more quadrants on gonioscopic examination
Intraocular pressure > 21mmHg on or off topical medication at least four weeks following laser iridotomy
Intra ocular pressure > 21 mm Hg after wash out regimen as described below for patients who are already on one medication and Iridotomy has been done at least 4 weeks ago.
Informed Consent
Age more than 21 years

Exclusion criteria

Age less than 21 years
Secondary causes of angle closure like subluxed lens, uveitis, trauma and neovascular glaucoma
Presence of advanced sight-threatening glaucoma defined as vertical cup-disc ratio > 0.9
Presence of significant synechial angle closure with > 6 clock hours of peripheral anterior synechiae (defined as abnormal adhesions of the iris to the angle that are at least half a clock hour in width and be at least to the anterior trabecular meshwork or higher on indentation gonioscopy)
Cataract that is deemed significant enough to require surgery during the course of the trial or that makes field testing or optic disc imaging not technically possible- visual acuity less than 20/40 due to any type of cataract.
Corneal endothelial cell count less than 1000 cells/mm2
Corneal abnormalities or infection
Previous intraocular surgery
Use of contact lens
Chronic use of topical or systemic steroids
Participation in another therapeutic drug study within the last 30 days
Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, respiratory disease, or cancer and life expectancy less than one year.